Milestone Pharmaceuticals (MIST) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Rani Therapeutics (RANI) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 60.9% versus a loss of 63.5%. Over five years, MIST leads with a -87.3% price change compared with -96.5% for RANI. Rani Therapeutics is the larger company by market cap ($90.0 million vs $88.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIST | RANI |
|---|---|---|
| Share price | $0.7073 | $0.6406 |
| Market cap | $88.06M | $90.02M |
| 1-day change | -10.98% | -5.79% |
| YTD return | -64.99% | -52.55% |
| 1-year return | -63.54% | -60.94% |
| 5-year return | -87.27% | -96.54% |
| EPS (TTM) | $-0.68 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.63M |
| Revenue growth (YoY) | — | +58.85% |
| Net income (latest FY) | $-63.06M | $-29.67M |
| Operating margin | — | -2345.99% |
| Net margin | — | -1817.09% |
| 52-week high | $3.06 | $3.87 |
| 52-week low | $0.704 | $0.613 |
| Distance from 52-week high | -76.89% | -83.45% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +728.50% | +1023.95% |
| Average volume | 1.42M | 720.45K |
| Shares outstanding | 124.50M | 115.42M |
| Employees | 38 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
MIST vs RANI FAQ
Which is bigger, Milestone Pharmaceuticals or Rani Therapeutics?
Rani Therapeutics (RANI) is larger, with a market capitalization of $90.02M compared with $88.06M for Milestone Pharmaceuticals (MIST).
Which stock has performed better over the past year, MIST or RANI?
RANI returned -60.94% over the past 12 months, compared with -63.54% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Milestone Pharmaceuticals and Rani Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.